Neumora Therapeutics Files 8-K on Security Holder Vote

Ticker: NMRA · Form: 8-K · Filed: May 30, 2025 · CIK: 1885522

Neumora Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyNeumora Therapeutics, INC. (NMRA)
Form Type8-K
Filed DateMay 30, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

TL;DR

Neumora shareholders voted on something May 28th. Details to follow.

AI Summary

Neumora Therapeutics, Inc. filed an 8-K on May 30, 2025, reporting on a matter submitted to a vote of its security holders on May 28, 2025. The company, formerly known as RBNC Therapeutics, Inc., is incorporated in Delaware and headquartered in Watertown, Massachusetts.

Why It Matters

This filing indicates a formal process where Neumora's shareholders are voting on a specific corporate matter, which could impact the company's governance or strategic direction.

Risk Assessment

Risk Level: low — This is a routine corporate filing about a shareholder vote, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

FAQ

What specific matter was submitted for a vote by Neumora Therapeutics' security holders?

The filing states that the report is for the 'Submission of Matters to a Vote of Security Holders' but does not specify the exact matter in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on May 28, 2025.

What is Neumora Therapeutics, Inc.'s former name?

Neumora Therapeutics, Inc.'s former name was RBNC Therapeutics, Inc.

Where are Neumora Therapeutics, Inc.'s principal executive offices located?

Neumora Therapeutics, Inc.'s principal executive offices are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472.

What is the SEC file number for Neumora Therapeutics, Inc.?

The SEC file number for Neumora Therapeutics, Inc. is 001-41802.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding Neumora Therapeutics, Inc. (NMRA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing